REG - Morgan Stanley Takeda Pharma.Co.Ltd - Form 8.5 (EPT/NON-RI) - TAKEDA PHARMACEUTICAL

Takeda Pharmaceutical CoAnnouncement

28/11/2018 10:40

RNS Number : 7704I
Morgan Stanley
28 November 2018
 


 
FORM 8.5 (EPT/NON-RI)
 
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN
EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)
Rule 8.5 of the Takeover Code (the "Code")
 
1.         KEY INFORMATION
 



(a) Name of exempt principal trader:


Morgan Stanley MUFG Securities Co., Ltd.




(b) Name of offeror/offeree in relation to whose relevant securities this form relates:
     Use a separate form for each offeror/offeree


Takeda Pharmaceutical Company Limited




(c) Name of the party to the offer with which exempt principal trader is connected:


Shire plc




(d) Date position held/dealing undertaken:
     For an opening position disclosure, state the latest practicable date prior to the disclosure


27 NOVEMBER 2018




(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to the offer?
     If it is a cash offer or possible cash offer, state "N/A"


YES - Shire plc



 
2.         POSITIONS OF THE EXEMPT PRINCIPAL TRADER                            
 
If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.
 
(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)
 



 
Class of relevant security:


 
Ordinary




 
 


Interests


Short positions




Number


%


Number


%




(1) Relevant securities owned and/or controlled:


11,731,287


1.50


29,947,681


3.82




(2) Cash-settled derivatives:
 


29,445,003


3.75


10,950,171


1.40




(3) Stock-settled derivatives (including options) and agreements to purchase/sell:


315,000


0.04


315,000


0.04




 
     TOTAL:


41,491,290


5.29


41,212,852


5.26



 
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).
 
(b)        Rights to subscribe for new securities (including directors' and other employee options)
 



Class of relevant security in relation to which subscription right exists:


N/A




Details, including nature of the rights concerned and relevant percentages:


N/A



 
 
3.         DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER
 
Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.
 
The currency of all prices and other monetary amounts should be stated.
 
(a)        Purchases and sales
 



Class of relevant security


 Purchases/sales


 Total   number of securities


 Highest price per unit paid/received


 Lowest price per unit paid/received




 Ordinary


 PURCHASES


 1,608,756


 4,476.0000 JPY


 4,175.2917 JPY




 Ordinary


 SALES


 1,679,662


 4,476.0000 JPY


 4,175.2917 JPY



 
 (b)       Cash-settled derivative transactions
 



Class of relevant security


 Product description
            e.g. CFD


 Nature of dealing
e.g. opening/closing a long/short position, increasing/reducing a long/short position


 Number of reference securities


 Price per unit




Ordinary


CFD


SHORT


900


4183.7777 JPY




Ordinary


CFD


SHORT


300


4226.0000 JPY




Ordinary


CFD


LONG


100


4203.0000 JPY




Ordinary


CFD


LONG


500


4187.4000 JPY




Ordinary


CFD


SHORT


11900


4199.6050 JPY




Ordinary


CFD


LONG


14900


4204.2147 JPY




Ordinary


CFD


LONG


16300


4192.2453 JPY




Ordinary


CFD


SHORT


400


4220.0000 JPY




Ordinary


CFD


SHORT


35300


4199.6940 JPY




Ordinary


CFD


LONG


45500


4226.1978 JPY




Ordinary


CFD


LONG


500


4192.0000 JPY




Ordinary


CFD


SHORT


400


4248.0000 JPY




Ordinary


CFD


LONG


400


4201.0000 JPY




Ordinary


CFD


LONG


1300


4210.1538 JPY




Ordinary


CFD


SHORT


3000


4230.3333 JPY




Ordinary


CFD


LONG


1800


4217.5000 JPY




Ordinary


CFD


LONG


600


4222.1666 JPY




Ordinary


CFD


SHORT


400


4180.0000 JPY




Ordinary


CFD


SHORT


1600


4248.0000 JPY




Ordinary


CFD


SHORT


2500


4248.0000 JPY




Ordinary


CFD


LONG


2500


4184.8787 JPY




Ordinary


CFD


LONG


800


4184.8787 JPY




Ordinary


CFD


LONG


100


4288.0000 JPY




Ordinary


CFD


SHORT


100


4194.1451 JPY




Ordinary


CFD


SHORT


9100


4194.1451 JPY




Ordinary


CFD


LONG


2600


4230.3448 JPY




Ordinary


CFD


LONG


600


4240.0000 JPY




Ordinary


CFD


LONG


300


4230.3448 JPY




Ordinary


CFD


SHORT


300


4288.0000 JPY




Ordinary


CFD


SHORT


100


4288.0000 JPY




Ordinary


CFD


LONG


44967


4216.6270 JPY




Ordinary


CFD


SHORT


600


4228.8333 JPY




Ordinary


CFD


SHORT


23400


4210.2400 JPY




Ordinary


CFD


LONG


129289


4293.9191 JPY




Ordinary


CFD


SHORT


140250


4449.2023 JPY




Ordinary


CFD


LONG


37600


4189.9973 JPY



 
 (c)       Stock-settled derivative transactions (including options)               
 
(i)         Writing, selling, purchasing or varying
 



Class of relevant security


 Product description             e.g. call option


 Writing, purchasing, selling, varying etc.


 Number of securities to which option relates


 Exercise price per unit


 Type   e.g. American, European etc.


 Expiry date


 Option money paid/ received per unit




N/A


N/A


N/A


N/A


N/A


N/A


N/A


N/A



 
(ii)        Exercise
 



Class of relevant security


Product description
e.g. call option


Exercising/ exercised against


Number of securities


Exercise price per unit




N/A


N/A


N/A


N/A


N/A



 
(d)        Other dealings (including subscribing for new securities)
 



Class of relevant security


Nature of dealing
e.g. subscription, conversion


Details


Price per unit (if applicable)




N/A


N/A


N/A


N/A



 
 
4.         OTHER INFORMATION
 
(a)        Indemnity and other dealing arrangements
 



Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included.  If there are no such agreements, arrangements or understandings, state "none"




 
None
 



 
(b)        Agreements, arrangements or understandings relating to options or derivatives
 



Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:
(i)  the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"




 
None
 



 
(c)        Attachments
 



Is a Supplemental Form 8 (Open Positions) attached?


YES



 
 



Date of disclosure:


28 NOVEMBER 2018




Contact name:


Craig Horsley




Telephone number:


+44(141) 245 7736



 
Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk.  The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.
 
The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk
 
 
 
 
 
 
SUPPLEMENTAL FORM 8 (OPEN POSITIONS)
 
DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.
Note 5(i) on Rule 8 of the Takeover Code (the "Code")
 
 
 
4.   KEY INFORMATION
 



Identity of person whose open positions are being disclosed:


Morgan Stanley MUFG Securities Co., Ltd.




Name of offeror/offeree in relation to whose relevant securities the disclosure relates:


Takeda Pharmaceutical Company Limited



 
2.         STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)
 
 



Class of relevant security


Product Description e.g call option


Written or Purchased


Number of Securities to which option or derivative relates


Exercise Price Per Unit (USD)


Type


Expiry Date




 Ordinary


 PUT


PURCHASED


 125,000


4507.0000 JPY


 European


13/12/2019




 Ordinary


 CALL


PURCHASED


 125,000


4507.0000 JPY


 European


13/12/2019




 Ordinary


 PUT


PURCHASED


 60,000


4596.0000 JPY


 European


14/06/2019




 Ordinary


 CALL


PURCHASED


 60,000


4596.0000 JPY


 European


14/06/2019




 Ordinary


 PUT


PURCHASED


 65,000


4414.0000 JPY


 European


14/06/2019




 Ordinary


 CALL


PURCHASED


 65,000


4414.0000 JPY


 European


14/06/2019




 Ordinary


 PUT


PURCHASED


 65,000


4414.0000 JPY


 European


13/12/2019




 Ordinary


 CALL


PURCHASED


 65,000


4414.0000 JPY


 European


13/12/2019



 
 
 
 
3.         AGREEMENTS TO PURCHASE OR SELL ETC.
 



Full details should be given so that the nature of the interest or position can be fully understood:




 
 
 
 
 



 
It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences ("CFDs") or spread bets.
 
The currency of all prices and other monetary amounts should be stated.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEOEAEFPADAPFFF